Skip to main content
. 2021 Nov 4;12:664645. doi: 10.3389/fendo.2021.664645

Table 3.

Correlation among severity, phenotype and pathogenicity predictions in patients with 4 variants in potentially POI genes.

Patients ID Origin Karyotype Phenotype Menarche(yrs) POI onset(yrs) Familiarity Variation(HGVS) Zigosity OVO-Array patients’ frequency (n = 64) gnomAD ver. 2.1.1 female population frequency VarSome predictionv.2.1.1 VarSome Criteria
6 Caucasian not available OD No Yes FIGLA(NM_001004311.3):c.364del:(p.Glu122LysfsTer45) Het 0.015625 Novel P PVS1,PM2,PP5,PP3
NOBOX(NM_001080413.3):c.1626del:(p.Phe543SerfsTer7) Het 0.015625 Novel P PVS1,PM2,PP5
NR5A1(NM_004959.5):c.1063G>A:(p.Val355Met) Het 0.03125 0.000122 LP PM1,PM2,PP5,PP2,PP3
NCOR2(NM_006312.6):c.3755C>A:(p.Pro1252Gln) Het 0.015625 Novel VUS PM2,PP3
7 Caucasian not available PA No No VWF(NM_000552.5):c.4517C>T:(p.Ser1506Leu) Het 0.046875 P PP5,PM1,PM2,PP2,PP3
VWF(NM_000552.5):c.4508T>C:(p.Leu1503Pro) Het 0.03125 Novel LP PM1,PM2,PM5,PP2,PP3
NOTCH3(NM_000435.3):c.2791A>G:(p.Ser931Gly) Het 0.015625 Novel LP PM1,PM2,PP2,PP3
TRRAP(NM_001244580.1):c.10171A>G:(p.Met3391Val) Het 0.015625 Novel VUS PM2,PP2
8 Caucasian not available eSA 16 18 No SAMD11(NM_152486.4):c.682_683insT:
(p.Pro228LeufsTer227)
Het 0.09375 0.000183 LB BS1
ATG4C(NM_032852.4):c.607dup: (p.Trp203LeufsTer4) Het 0.015625 0.000659 VUS PP3,BS1
NOTCH4(NM_004557.4):c.2945C>T:(p.Thr982Ile) Het 0.015625 Novel VUS PM2,PP3,BP1
RMI1(NM_024945.3):c.746C>T:(p.Ala249Val) Het 0.015625 Novel VUS PM2,PP3
9 Caucasian not available eSA 14 14 No NR5A1(NM_004959.5):c.502G>C:(p.Ala168Pro) Het 0.015625 Novel VUS PM2,PP2,BP4
SYNE1(NM_182961.4):c.16709A>G:(p.Gln5570Arg) Het 0.015625 Novel LP PP3,PM2
RAD50(NM_005732.4):c.2165dup:(p.Glu723GlyfsTer5) Het 0.015625 0.000301 P PVS1,PP5,PM2,PP3
ADAMTS5(NM_007038.5):c.1729G>A:(p.Gly577Ser) Het 0.03125 0.0151 VUS PP3,BS1
10 Caucasian 46,XX SA 13 25 ADAMTS4(NM_005099.6):c.803G>A:(p.Arg268Gln) Het 0.015625 VUS PM2,BP4
DHCR24(NM_014762.4):c.1046C>G:(p.Pro349Arg) Het 0.015625 0.0000087 VUS PM2,PP2,PP3
FSHR(NM_000145.4):c.491C>T:(p.Ser164Phe) Het 0.015625 Novel VUS PM2,PP2,PP3
RAD52(NM_134424.4):c.175G>A:(p.Gly59Arg) Het 0.015625 0.000699 VUS PP3
11 Caucasian 46,XX SA 11 14 No APC2(NM_005883.3):c.2887C>T:(p.Arg963Trp) Het 0.015625 0.0000135 VUS PM2,PP3,BP1
ATG2A(NM_015104.3):c.4414G>C:(p.Gly1472Arg) Het 0.015625 0.0000174 VUS PM2,PP3,BP1
COL6A1(NM_001848.3):c.350T>C:(p.Val117Ala) Het 0.015625 0.000982 VUS PM2,PP2,PP3
KPNA2(NM_002266.4):c.445T>C:(p.Ser149Pro) Het 0.015625 Novel VUS PM2.PP3
12 Caucasian not available SA 11 25 No LARS2(NM_015340.4):c.2192A>T:(p.Tyr731Phe) Het 0.015625 Novel VUS PM2,PP2,BP4
RBBP8(NM_002894.3):c.2516G>A(p.Arg839Gln) Het 0.03125 0.000415 VUS PM2,PP3,BP1
THBS2(NM_003247.5):c.1183G>A:(p.Val395Met) Het 0.015625 0.0000528 VUS PP3,BS1,BP1
RIPK1(NM_003804.6):c.700G>A:(p.Glu234Lys) Het 0.015625 0.000684 VUS PM2,PP2,BP4,BP6
13 Caucasian not available SA 12 21 No ATM(NM_000051.4):c.7375C>T:(p.Arg2459Cys) Het 0.015625 0.0000433 VUS PM1,PM2,PP3
NCOR2(NM_006312.6):c.3709G>A:(p.Val1237Ile) Het 0.015625 0.00000886 VUS PP3
POLG(NM_001126131.2):c.752C>T:(p.Thr251Ile) Het 0.03125 0.00147 LP PS3,PM2,PP2,PP5
POLG(NM_001126131.2):c.1760C>T:(p.Pro587Leu) Het 0.03125 0.0015 P PP5,PS3,PM2,PP2,PP3
14 Caucasian 46,XX SA 12 16 Yes VWF(NM_000552.5):c.4517C>T:(p.Ser1506Leu) Het 0.046875 Novel P PP5,PM1,PM2,PP2,PP3
VWF(NM_000552.5):c.5641G>A:(p.Asp1881Asn) Het 0.015625 Novel VUS PM2,PP2,PP3
LGR4(NM_018490.5):c.2531A>G:(p.Asp844Gly) Het 0.015625 0.0124 VUS PP3,BS1,BP1,BP6
HK3(NM_002115.3):c.2389G>A:(p.Glu797Lys) Het 0.015625 0.000113 VUS PP3,BS1,BP1

OD, ovarian dysgenesis; PA, primary amenorrhea; eSA, early secondary amenorrhea; SA, secondary amenorrhea; Het, heterozygosity; P, pathogenic; VUS, variant of unknown significance; LP, likely pathogenic; LB, likely benign.